Taking the lead - Sharing best practice in intravenous bisphosphonate use in urological cancers

European Journal of Oncology Nursing

Volumn 16, Issue 1, 2012, Pages 42-53

  Jensen, Bente Thoft ^a   Dielenseger, Pascale ^b   Drudge Coates, Lawrence ^c   Flynn, Karen ^d   Hieronymi, Susanne ^e   Erik van Muilekom, H A M ^f   Pieters, Ronny ^g   Voss, Lisbeth Bjerregaard ^h  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b French Oncology Nurses Society   (France)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d Irish Cancer Society   (Ireland)

^e KRANKENHAUS NORDWEST   (Germany)

^f ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^g GHENT UNIVERSITY HOSPITAL   (Belgium)

^h NAESTVED HOSPITAL   (Denmark)

Author keywords

Bisphosphonates; Bone metastases; Cancer; Drug administration; Multidisciplinary team working; Nurse specialist; Osteonecrosis; Urology; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ARTICLE; BONE TUMOR; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; JAW OSTEONECROSIS; MALE; METASTASIS; MULTICENTER STUDY; NURSING; PATHOLOGY; PRACTICE GUIDELINE; URINARY TRACT CANCER;

BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PRACTICE GUIDELINES AS TOPIC; UROLOGIC NEOPLASMS;

EID: 84455171337     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/j.ejon.2011.02.006     Document Type: Article

References (107)

1. Aapro M., Abrahamsson P.A., Body J.J., Coleman R.E., Colomer R., Costa L., Crinò L., Dirix L., Gnant M., Gralow J., Hadji P., Hortobagyi G.N., Jonat W., Lipton A., Monnier A., Paterson A.H., Rizzoli R., Saad F., Thürlimann B. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals of Oncology 2008, 19:420-432.
2. Abrahm J.L. Assessment and treatment of patients with malignant spinal cord compression. Journal of Supportive Oncology 2004, 2:377-401.
3. Aragon-Ching J.B., Ning Y.M., Chen C.C., Latham L., Guadagnini J.P., Gulley J.L., Arlen P.M., Wright J.J., Parnes H., Figg W.D., Dahut W.L. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Investigation 2009, 27:221-226.
4. Bader P., Echtle D., Fonteyne V., De Meerleer G., Papaioannou E.G., Vranken J.H. Guidelines on Pain Management. European Association of Urology 2009, (Accessed October 2009). http://www.uroweb.org/nc/professional-resources/guidelines/online/.
5. Badros A., Weikel D., Salama A., Goloubeva O., Schneider A., Rapoport A., Fenton R., Gahres N., Sausville E., Ord R., Meiller T. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. Journal of Clinical Oncology 2006, 24:945-952.
6. Bagán J., Blade J., Cozar J.M., Constela M., Sanz R.G., Veiga F.G., Lahuerta J., Lluch A., Massuti B., Morote J., San Miguel J.F., Solsona E. Recommenations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Medicina Oral, Patología Oral y Cirugía Bucal 2007, 12:E336-E340.
7. Bellmunt J., Albiol S., Kataja V. Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology 2009, 20(Suppl. 4):iv79-iv80.
8. Berenson J.R. Recommendations for zoledronic acid treatment of patients with bone metastases. The Oncologist 2005, 10:52-62.
9. Berruti A., Tucci M., Terrone C., Gorzegno S., Scarpa R.M., Angeli A., Dogliotti L. Background to and management of treatment-related bone loss in prostate cancer. Drugs and Aging 2002, 19:899-910.
10. Brown J.E., Coleman R.E. The present and future role of bisphosphonates in the management of patients with breast cancer. Breast Cancer Research 2002, 4:24-29.
11. Brown J.E., Neville-Webbe H., Coleman R.E. The role of bisphosphonates in breast and prostate cancers. Endocrine-Related Cancer 2004, 11:207-224.
12. Brunello A., Saia G., Bedogni A., Scaglione D., Basso U. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 2009, 44:173-175.
13. Cancerweb Hypercalcemia. National Cancer Institute 2009, (Accessed September). http://www.cancerweb.ncl.ac.uk/cancernet/304462.html.
14. Cafro A.M., Barbarano L.A., Andriani A., D'Avanzo G., Nichelatti M., Gaglioti D., Taroni A., Gargantini L., Draisci M.G., Morra E. Osteonecrosis of the jaw associated with chronic bisphosphonates therapy: an Italian experience. Blood 2005, 106:5152. (ASH Annual Meeting Abstracts).
15. Castellucci P., Fuccio C., Rubello D., Schiavina R., Santi I., Nanni C., Allegri V., Montini G.C., Ambrosini V., Boschi S., Martorana G., Marzola M.C., Fanti S. Is there a role for (11)C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with w mild PSA increase <1.5 mg/ml?. European Journal of Nuclear Medicine and Molecular Imaging 2011, 38:55-63.
16. Coleman R.E. Skeletal complications of malignancy. Cancer 1997, 80:1588-1594.
17. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treatment Reviews 2001, 27:165-176.
18. Coleman R.E. Risks and benefits of bisphosphonates. British Journal of Cancer 2008, 98:1726-1740.
19. S3 Guideline for Prostate Cancer Deutsche Gesellschaft für Urologie eV 2009, DGU (Deutsche Gesellschaft für Urologie eV), (Accessed October 2009). http://www.dgu.de/.
20. Dimopoulos M.A., Kastritis E., Anagnostopoulos A., Melakopoulos I., Gika D., Moulopoulos L.A., Bamia C., Terpos E., Tsionos K., Bamias A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006, 91:968-971.
21. Dimopoulos M.A., Kastritis E., Barnia C., Melakopoulos I., Gika D., Roussou M., Migkou M., Eleftherakis-Papaiakovou E., Christoulas D., Terpos E., Bamias A. Reduction of osteonecrosis of the jaw (ONJ after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology 2009, 20:117-120.
22. Drake M.T., Clarke B.L., Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clinic Proceedings 2008, 83:1032-1045.
23. Durie B.G., Katz M., Crowley J. Osteonecrosis of the jaw and bisphosphonates. New England Journal of Medicine 2005, 353:99-102.
24. S3- Guideline Osteoporosis. Dachverband Osteologie 2009, DVO (Dachverband Osteologie), (Accessed October 2009). http://www.dv-osteologie.de.
25. Edwards B.J., Hellstein J.W., Jacobsen P.L., Kaltman S., Mariotti A., Migliorati C.A. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy. Journal of the American Dental Association 2008, 139:1674-1677. for the American Dental Association Council in Scientific Affairs Expert Panel on bisphosphonate associated osteonecrosis of the jaw.
26. Product Information for Prolia (Denosumab) European Medicines Agency EMEA/H/C/001120 2010, EMA (European Medicines Agency). http://www.ema.europa.eu.
27. Questions and Answers on the Review of Bisphosphonates and the Risk of Osteonecrosis of the Jaw. European Medicines Agency: EMEA/CHMP/292475/2009 2009, EMA (European Medicines Agency). http://www.ema.europa.eu.
28. Escudier B., Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology 2009, 20(Suppl. 4):iv81-iv82.
29. Estilo C.L., Fornier M., Farooki A., Carlson D., Bohle G., Huryn J.M. Osteonecrosis of the jaw related to bevacizumab. Journal of Clinical Oncology 2008, 26:4037-4038.
30. Safety Alerts for Human Medical Products - Zometa (Zoledronic Acid), Aredia (Pamidronate Disodium) -05/18/2005; 2005 Safety Alerts for Human Medicines - Zometa (Zoledronic Acid) -03/25/2005. FDA 2005, FDA (Food and Drug Administration), 2005, (Accessed October 2009). http://www.fda.gov/Safety/Medwatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts.
31. Felix J., Andreozzi V., Soares M., Gervásio H., Moreira A., Costa L., Marcelo F., Peralta F., Furtado I., Pina F., Albuquer C., Santos A., Passos-Coelho J.L. Treatment Costs of Skeletal-related (SRE) in Patients with Metastatic Breast or Prostate Cancer. Poster Presented at 14th European Cancer Conference (ECCO) Abstract Number 1.241 2007, for the Portuguese Group for the Study of Bone Metastases.
32. Fizazi K., Lipton A., Mariette X., Body J.-J., Rahim Y., Gralow J.R., Gao G., Wu L., Sohn W., Jun S. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. Journal of Clinical Oncology 2009, 27:1564-1571.
33. Fizazi K., Carducci M.R., Smith R., Damião J.E., Brown L., Karsh P., Milecki H., Wang R.D., Dansey C., Goessl D. A randomized phase III trial of denosumab versis zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. Journal of Clinical Oncology 2010, 28(18s). (Suppl; abstr LBA4507).
34. Gainor B.J., Buchert P. Fracture healing in metastatic bone disease. Clinical Orthopaedics and Related Research 1983, 178:297-302.
35. Gálvez T., Ribera V., González-Escalas J.R., Souto A., Cánovas M.L., Castro A., Herrero B., de Los Angeles Maqueda M., Castilforte M., Marco-Martínez J.J., Pérez C., Vicente-Fatela L., Md C.N., Orduña M.J., Padrol A., Reig E., Carballido J., Cózar J.M. Analgesic efficacy of zoledronic acid and its effect on functional status of prostate cancer patients with metastasis. Patient Preference and Adherence 2008, 2:215-224.
36. Gebara S.N., Moubayed H. Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates. American Journal of Health-System Pharmacy 2009, 66(17):1541-1547.
37. Gnant M., Mlineritsch B., Stoeger H., Luschin-Ebengreuth G., Poestlberger S., Dubsky P.C., Jakesz R., Singer C.F., Eidtmann H., Greil R. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer. Journal of Clinical Oncology 2010, 28(Suppl. 15s). abstract 533.
38. Gralow J.R. Bisphosphonate risks and benefits: finding a balance. Journal of Clinical Oncology 2010, 28(3):4873-4876.
39. Greuter S., Schmid F., Ruhstaller T., Thuerlimann B. Bevacizumab-associated osteonecrosis of the jaw. Annals of Oncology 2008, 19:2091-2092.
40. Grewal V.S., Fayans E.P. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management. The New York State Dental Journal 2008, 74:38-44.
41. Halpin R.J., Bendok B.R., Liu J.C. Minimally invavsive treatments for spinal metastases: vertebroplasty, kyphoplasty, and radiofrequency ablation. The Journal of Supportive Oncology 2004, 2:335-339.
42. Heidenreich A., Bolla M., Joniau S., van der Kwast T.H., Matveev V., Mason M.D., Mottet N., Schmid H.P., Wregel T., Zattoni F. Guidelines on Prostate Cancer (March 2009 Update). European Association of Urology 2009, (Accessed October 2009). http://www.uroweb.org/professional-resources/guideline/.
43. Heidenreich A., Albers P., Classen J., Graefen M., Gschwend J., Kortzerke J., Krege S., Lehmann J., Rohde D., Schmidberger H., Uder M., Zeeb H. Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urologia Internationalis 2010, 85:1-10.
44. Henry D., von Moos R., Vadhan-Raj S., Hungria V., Spencer A., Hirsh V., Wang J., Jun S., Yeh H., Dansey R. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. European Journal of Cancer 2009, 7(3):12. (Late breaking abstract 20).
45. Hoff A.O., Toth B.B., Altundag K., Johnson M.M., Warneke C.L., Hu M., Nooka A., Sayegh G., Guarneri V., Desrouleaux K., Cui J., Adamus A., Gagel R.F., Hortobagyi G.N. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. Journal of Bone and Mineral Research 2008, 23(6):826-836.
46. Holmes-Walker D.J., Woo H., Gurney H., Do V.T., Chipps D.R. Maintaining bone health in patients with prostate cancer. The Medical Journal of Australia 2006, 184(4):176-179.
47. Horwich A., Parker C., Kataja V. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology 2009, 20(Suppl. 4):iv76-iv78.
48. Israeli R.S., Ryan C.W., Jung L.L. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. Journal of Urology 2008, 179(2):414-423.
49. Inspectie voor de Gezondheidszorg [homepage on the Internet]. Available from: http://www.igz.nl/.
50. Bisphosphonates and Osteonecrosis of the Jaw: Update on Risk Minimisation Including New Recommendations on Preventative Dental Measures. IMB IMF Article. 7th February 2010 2010, IMB (Irish Medicines Board).
51. Jacofsky D.J., Haidukewych G.J. Management of pathologic fractures of the proximal femur: state of the art. Journal of Orthopaedic Trauma 2004, 18:459-469.
52. Jahanzeb M., Hirsh V. Bisphosphonates in lung cancer: more than a palliative therapy?. Seminars in Oncology 2010, 37(Suppl. 1):S45-S52.
53. Khan A.A., Sándor G.K., Dore E., Morrison A.D., Alshali M., Amin F., Peters E., Hanley D.A., Chaudry S.R., Dempster D.W., Glorieux F.H., Nevill A.J., Talwar R.M., Clokie C.M., Mardini M., Paul T., Khosla S., Josse R.G., Sutherland S., Lam D.K., Carmichael R.P., Blanas N., Kendler D., Petak S., St-Marie L.G., Brown J., Evans A.W., Rios L., Compston J.E. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. Journal of Rheumatology 2008, 35(7):1391-1397. Canadian Association of Oral and Maxillofacial Surgeons.
54. King A.E., Umland E.M. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates. Pharmacotherapy 2008, 28(5):667-677.
55. Kohno N., Aogi K., Minami H., Nakamura S., Asaga T., Iino Y., Watanabe T., Goessl C., Ohashi Y., Takashima S. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomised, placebo-controlled trial. Journal of Clinical Oncology 2005, 23:3314-3321.
56. Krishnan A., Arslanoglu A., Yildirm A. Imaging findings of bisphosphonate-related osteonecrosis of the jaw with emphasis on early magnetic resonance imaging findings. Radiology 2010, 257(2):523-531.
57. Kyrgidis A., Andreadis C. Clinical characterization might help in preventing osteonecrosis of the jaw. Clinical Cancer Research 2008, 14(24):8321.
58. Le Plan Cancer 2009-2013, http://www.plan-cancer.gouv.fr.
59. Lipton A., Zheng M., Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003, 98(5):962-969.
60. Liu H., Paige N.M., Goldzweig C.L., Wong E., Zhou A., Suttorp M.J., Munjas B., Orwoll E., Shekelle P. Screening for osteoporosis in men: a systematic review for an American College of Physicians Guideline. Annals of Internal Medicine 2008, 148:685-701.
61. Luz M.A., Aprikian A.G. Preventing bone complications in advanced prostate cancer. Current Oncology 2010, 17(Suppl. 2):S65-S71.
62. Major P. Optimal management of metastatic bone disease. European Journal of Oncology Nursing 2007, 11(Suppl. 2):S32-S37.
63. Malcolm J.B., Derweesj I.H., Kincade M.C., DiBlasio C.J., Lamar K.D., Wake R.W., Patterson A.L. Osteoporosis and fractures after androgen deprivation initiation for prostate cancer. Canadian Journal of Urology 2007, 14:3551-3559.
64. Migliorati C.A., Siegel M.A., Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncology 2006, 7(6):508-514.
65. Montefusco V., Gay F., Spina F., Miceli R., Maniezzo M., Ambrosini M.T., Farina L., Piva S., Palumbo A., Boccadoro M., Corradini P. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia and Lymphoma 2008, 49(11):2156-2162.
66. Morgan C., Wagstaff J. Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases?. Acta Oncologica 2009, 48(6):882-889.
67. Morgan G., Davies F., Gregory W., Bell S.E., Szubert A., Navarro Coy N., Drayson M., Owen R.G., Jackson G.H., Child J.A. Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): results of the Medical Research Council (MRC) Myeloma IX study. Journal of Clinical Oncology 2010, 28(Suppl. 15s). abstract 8021.
68. Mortimer J.E., Pal S.K. Safety considerations for use of bon-targeted agenst i patients with cancer. Seminars in Oncology 2010, 37(Suppl. 1):S66-S72.
69. Guidance on Cancer Services. Improving Outcomes in Urological Cancers. The Manual 2002, NICE, NHS National Institute for Health and Clinical Excellence.
70. Clinical Guidelines CG58: Prostate Cancer: Diagnosis and Treatment. Joint Implementation Statement 2009, NICE and BAUS, NHS National Institute for Health and Clinical Excellence.
71. Parkin D.M., Bray F., Pisani P. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer 2001, 94:153-156.
72. Pavlakis N., Schmidt R., Stockler M. Bisphosphonates for breast cancer. Cochrane Database of Systematic Reviews 2005, 20(3). CD003474.
73. Pazianas M., Miller P., Blumentals W.A., Bernal M., Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporoses treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clinical Therapeutics 2007, 29(8):1548-1558.
74. Pozzi S., Marcheselli R., Sacchi S., Baldini L., Angrilli F., Pennese E., Quarta G., Stelitano C., Caparotti G., Luminari S., Musto P., Natale D., Broglia C., Cuoghi A., Dini D., Di Tonno P., Leonardi G., Pitini V., Polimeno G., Ponchio L., Masini L., Musso M., Spriano M., Pollastri G. Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leukemia and Lymphoma 2007, 48(1):56-64. Gruppo Italiano Studio Linfomi.
75. Reischauer C., Froehlich J.M., Koh D.M., Graf N., Padevit C., John H., Binkert C.A., Boesiger P., Gutzeit A. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functonal diffusion maps - initial observations. Radiology 2010, 257(2):523-531.
76. Ripamonti C.I., Maniezzo M., Camoa T., Fagnoni E., Brunelli C., Saibene G., Bareggi C., Ascani L., Cislaghi E. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Annals of Oncology 2009, 20(1):137-145.
77. Rogers S., Rahman N., Ryan D., Flint S., Healy C., Stassen L.F. Guidelines for treating patients taking bisphosphonates priori to dental extractions. Journal of the Irish Dental Association 2010, 56(1):40.
78. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., Apffelstaedt J., Hussein M., Coleman R.E., Reitsma D.J., Seaman J.J., Chen B.L., Ambros Y. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osetolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer Journal 2001, 7(5):377-387.
79. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., Apffelstaedt J., Hussein M., Coleman R.E., Reitsma D.J., Chen B.L., Seaman J.J. Long-term efficacy and safety of zoledronic acid compared withpamidronate disodium in the treatment of skeletal complication in patients with advanced multiple myeloma or breast carcinoma: a randomised, double-blind, multicenter, comparative trial. Cancer 2003, 98(8):1735-1744.
80. Ross J.R., Saunders Y., Edmonds P.M., Patel S., Wonderling D., Normand C., Broadley K. A systematic review of the role of bisphosphonates in metastatic disease. Health Technology Assessment 2004, 8(4):1-176.
81. Ruggiero S.L., Dodson T.B., Assaei A., Landesberg R., Marx R.E., Mehrotra B. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws - 2009 update. Journal of Oral and Maxillofacial Surgery 2009, 67(Suppl. 5):2-12.
82. Ruggiero S., Gralow J., Marx R.E., Hoff A.O., Schubert M.M., Huryn J.M., Toth B., Damato K., Valero V. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. Journal of Oncology Practice 2006, 2(1):7-14.
83. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin J.L., Vinholes J.J., Goas J.A., Chen B. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute 2002, 94:1458-1468.
84. Saad F., Olsson C., Schulman C.C. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. European Urology 2004, 46:731-740.
85. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., Chin J.L., Vinholes J.J., Goas J.A., Zheng M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. Journal of the National Cancer Institute 2004, 96:879-882. Zoledronic Acid Prostate Cancer Study Group.
86. Saad F., Chen Y.M., Gleason D.M., Chin J. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clinical Genitourinary Cancer 2007, 5(6):390-396.
87. Saad F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treatment Reviews 2008, 34(2):183-192.
88. Sambrook P., Oliver I., Goss A. Bisphosphonates and osteonecrosis of the jaw. Australian Family Physician 2008, 35(10):801-803.
89. Saylor P.J., Smith M.R. Bone health and prostate cancer. Prostate Cancer and Prostatic Diseases 2010, 13:20-27.
90. Shahinian V.B., Kuo Y.-F., Freeman J.L., Goodwin J.S. Rick of fracture after androgen deprivation therapy for prostate cancer. New England Journal of Medicine 2005, 352:154-164.
91. Small E.J., Smith M.R., Seaman J.J., Petrone S., Kowalski M.O. Combined analysis of two multicenter, randomised, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. Journal of Clinical Oncology 2003, 21:4277-4284.
92. Smith J.A., Soloway M.S., Young M.J. Complications of advanced prostate cancer. Urology 1999, 54(Suppl. 6A):8-14.
93. Smith M.R., McGovern F.J., Fallon M.A., Schoenfield D., Kantoff P.W., Finkelstein J.S. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer 2001, 91:2238-2245.
94. Smith M.R., McGovern F.J., Zeitman A.L., Fallon M.A., Hayden D.L., Schoenfeld D.A., Kantoff P.W., Finkelstein J.S. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. New England Journal of Medicine 2001, 345(13):948-955.
95. Stopeck A.T., Lipton A., Body J.J., Steger G.G., Tonkin K., de Boer R.H., Lichinitser M., Fujiwara Y., Yardley D.A., Viniegra M., Fan M., Jiang Q., Dansey R., Jun S., Braun A. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Journal of Clinical Oncology 2010, 28:5132-5139.
96. Tanvetyanon T., Stiff P.J. Management of the adverse effects associated with intravenous bisphosphonates. Annals of Oncology 2006, 17:897-907.
97. Tosi P., Catalano L., D'Arco A., Ronconi S., Cellini C., Offidani M., Perrone G., Ceccolini M., Brioli A., Tura S., Baccarani M., Cavo M. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 2006, 108(12):3951-3952.
98. Van den Wyngaert T. Osteonecrosis of the jaw (ONJ) might explain the increased oral surgery risk in cancer patients treated with bisphosphonates. Journal of Evidence Based Dental Practice 2007, 7(3):132-135.
99. Wang E.P., Kaban L.B., Strewler G.J., Raje N., Troulis M.J. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. Journal of Oral and Maxillofacial Surgery 2007, 65(7):1328-1331.
100. Wilkinson G.S., Baillargeon J., Kuo Y.-F., Freeman J.L., Goodwin J.S. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. Journal of Clinical Oncology 2010, 28:4898-4905.
101. Wilkinson A.N., Viola R., Brundage M.D. Managing skeletal related events resulting from bone metastases. British Medical Journal 2008, 337:a2041.
102. Wirth M., Tammela T., Debruyne F., Tubaro A., Witjes W., Patel A., Huland H., Miller K., Cicalese V., Gomez Veiga F. Effectiveness of Zoledronic Acid for the Prevention of Bone Metasatases in High-risk Prostate Cancer Patients. A Randomised, Open Label, Multicenter Study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologi (AUO). A Report of the ZEUS Study. ASCO2008 Genitourinary Cancers Symposium Abstract 184 2008, (Accessed October 2009). http://www.asco.org/ASCOv2/Meetings/Abstracts.
103. Wong R., Wiffen P.J. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database of Systematic Reviews 2002, (2). CD002068.
104. Woo S.B., Hellstein J.W., Kalmar J.R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine 2006, 144:753-761.
105. Yuen K.K., Shelley M., Sze W.M., Wilt T., Mason M.D. Bisphosphonates for advanced prostate cancer. Cochrane Database of Systematic Reviews 2006, 18(4). CD006250.
106. Zafeirakis A. Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer. Hippokratia 2010, 14(3):164-169.
107. Zaghloul M.S., Boutrus R., El-Hsieny H., A-Kader Y., El-Attar I., Nazmy M. A controlled prospective randomized placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer patients. Journal of Clinical Oncology 2008, 26(Suppl)). A5033.